2024 AUA preview: Dr. Tawagi on top research in bladder cancer
Karine Tawagi, MD, highlights several studies in bladder cancer being presented at the 2024 American Urological Association Annual Meeting.
In this video, Karine Tawagi, MD, discusses several studies in bladder cancer being presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Tawagi is an assistant professor of medicine and a genitourinary medical oncologist at the University of Illinois in Chicago.
The following abstracts were previewed:
1. PD30-09 (Prasad et al): Response to primary chemoablation with UGN-102 in patients with new or recurrent LG IR NMIBC: Post-hoc analysis of the ATLAS trial
2. PD48-02 (Vilaseca et al): First safety and efficacy results of the TAR-210 erdafitnib intravesical delivery system in patients with non-muscle-invasive bladder cancer with select FGFR alterations
3. PD48-01 (Boorjian et al): Efficacy of nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: Final results from a phase 3 trial
4. Pivotal results from BOND-003: A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (Tyson et al)
5. PD34-10 (Necchi et al): First results of Nure-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (PTS) with muscle-invasive bladder cancer (MIBC)
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
